Recent Advances in Prostate Cancer Treatment and Drug Discovery
Explore this paper's citation graph
Summary
The identification of improved, personalized treatments will be much supported by the major progress recently made in the molecular characterization of early- and late-stage prostate cancer using “omics” technologies, and should greatly help in the choice of novel targeted therapies best tailored to the needs of patients.
- Type
- review
- Published
- 2018-05-01
- Cited by
- 228
- References
- 185
- Access
- Open access
- OpenAlex
- https://openalex.org/W2799375096
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13690680
Keywords
Enzalutamide, Prostate cancer, Medicine, Docetaxel, Abiraterone acetate
References
- Treatment options for localized prostate cancer.
- Androgen receptor-mediated gene repression.
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
- Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
- Integrative clinical genomics of advanced prostate cancer
- The genomic evolution of human prostate cancer
- The influence of subclonal resistance mutations on targeted cancer therapy
- Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
- ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
- Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer
- Targeting BET bromodomains for cancer treatment.
- Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer
- A Systematic Review of Histone Lysine‐Specific Demethylase 1 and Its Inhibitors
- The Mutational Landscape of Prostate Cancer
- The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
- Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer
- Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.
- The polycomb group protein EZH2 is involved in progression of prostate cancer
- Targeting Fibroblast Growth Factor Pathways in Prostate Cancer
- High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Cited by
- Prostate cancer immunotherapy: where are we and where are we going?
- The effects of flutamide on cell-cell junctions in the testis, epididymis, and prostate.
- Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
- Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions
- Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G1 Cell Cycle Arrest
- The induction of Maspin expression by a glucosamine-derivative has an antiproliferative activity in prostate cancer cell lines.
- Efficient Prostate Cancer Therapy with Tissue-Specific Homing Peptides Identified by Advanced Phage Display Technology
- The Secret Life of Translation Initiation in Prostate Cancer
- Steroid Receptor Signallings as Targets for Resveratrol Actions in Breast and Prostate Cancer
- Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
- Tumor protein D52 (isoform 3) interacts with and promotes peroxidase activity of Peroxiredoxin 1 in prostate cancer cells implicated in cell growth and migration.
- Prostate Cancer National Summit's Call to Action.
- Bicalutamide-induced Eosinophilic Pneumonitis - A Serendipitous Diagnosis
- The creation of reagents fibulin-1C/D and truncates for protein purification and apoptotic ability on PCa cell lines
- Dysregulated Transcriptional Control in Prostate Cancer
- Cytotoxic Effects of Juglone and Pterocarya fraxinifolia on Prostate Cancer Cells
- Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer
- Reduced pim-1 expression increases chemotherapeutic drug sensitivity in human androgen-independent prostate cancer cells by inducing apoptosis.
- Protective effect of Chuquiraga spinosa Lessing associated with simvastatin on N-Nitroso-N-methylurea (NMU)-induced prostate cancer in rats
- The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Related papers
- Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug–Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
- [Descriptive study on contraceptive requirements for clinical trials in Spain. Do we need a debate?].
- Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
- Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
- Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer
- A drug-drug interaction study on the combination of cabazitaxel with enzalutamide in patients with metastatic castration-resistant prostate cancer.
- [Docetaxel-Cabazitaxel-Enzalutamide Versus Docetaxel-Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer].
- Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
- [Treatment of metastatic castration-resistant prostate cancer].
- Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate.